Work

Development of Theranostic 177Lu-Labeled Polymeric Nanoparticles (177Lu-PNPs) for the Treatment of Head and Neck Cancer

Year: 2025

Type: article

Abstract: High Resolution Image Download MS PowerPoint Slide This study presents the development of 177 Lu-labeled polymeric nanoparticles (PNPs) for theranostic applications in head and neck cancer, utilizing both near-infrared II (NIR-II) and SPECT imaging for targeted delivery and monitoring. The PNPs were surface-modified with ethylenediamine and chelated with DTPA to enable 177 Lu radiolabeling, achieving a radiochemical yield of 15.4% ± 3.2% and high purity (>95%). The radiolabeling process preserved the size distribution and optical properties of PNPs, facilitating their use in NIR-II imaging, which confirmed effective tumor delivery with peak uptake at 24 h postinjection. Photothermal therapy (PTT) combined with 177 Lu-PNPs significantly enhanced tumor uptake and therapeutic efficacy, as shown by tumor growth suppression and extended survival in treated mice. Importantly, mice receiving the 177 Lu-PNPs-PTT combination therapy exhibited minimal toxicity, as indicated by stable body weight and unaltered organ histology on H&E staining. These findings demonstrate the potential of 177 Lu-PNPs as a safe and effective multifunctional platform for imaging-guided photothermal-radionuclide cancer therapy.

Source: ACS Applied Bio Materials

DOI: 10.1021/acsabm.5c00579

Authors: Hsin-Hua Hsieh, Shih-Po Su, Yang-Hsiang Chan, Huihua Kenny Chiang, Yi-Jang Lee, Chun-Yi Wu

Institutions: National Yang Ming Chiao Tung University, Genomics Research Center, Academia Sinica, Academia Sinica, Kaohsiung Medical University

Language: English

Topic: Nanoplatforms for cancer theranostics

Subfield: Biomedical Engineering

Field: Engineering

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500